The newspaper 'La Vanguardia' published a report on the new test that Transbiomed, VHIR’s spin-off, is developing in order to diagnose the early stages of prostate cancer, using urine analysis to reduce the high number of unnecessary biopsis.Dr. Jaume Reventós, scientific adviser of Amadix, and head of the Research Unit in Biomedicine and Translational Oncology at Vall d’Hebron Institute of Research (VHIR), leads this new diagnosis system which detects in the urine up to three biomarkers of this type of cancer. The new test was proved successfully in 200 patients at Vall d’Hebron University Hospital and the second stage will be validated in a set of ten hospitals.The report, titled “Más y mejor vigilancia para la próstata”, was published the 17th of March in the Money section of 'La Vanguardia'.Biocat also dedicated a report on this test published the 8th of February.